Improved bioavailability of epoxyeicosatrienoic acids reduces TP-receptor agonist-induced tension in human bronchi

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 301, Issue 5, 2011, Pages

  Senouvo, Farid Yannick ^a   Tabet, Yacine ^a   Morin, Caroline ^a   Albadine, Roula ^b   Sirsois, Chantal ^a   Rousseau, Eric ^a  

^a UNIVERSITY OF SHERBROOKE   (Canada)

^b UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

Airway smooth muscle; N (methylsulfonyl) 2 (2 propynyloxy) benzenehexanamide; Thromboxane a; Thromboxane prostanoid receptor; Trans 4 4 (3 adamantan 1 yl ureido) cyclohexyloxy benzoic acid; U 46619

Indexed keywords

14,15 EPOXY 5,8,11 ICOSATRIENOIC ACID; 15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; BENZOIC ACID DERIVATIVE; EPOXYICOSATRIENOIC ACID; THROMBOXANE RECEPTOR;

ARTICLE; BIOAVAILABILITY; BRONCHUS; DRUG EFFECT; HUMAN; HUMAN TISSUE; LUNG; LUNG PRESSURE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SMOOTH MUSCLE; TISSUE CULTURE;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; 8,11,14-EICOSATRIENOIC ACID; ANIMALS; ARACHIDONIC ACID; BENZOIC ACIDS; BLOTTING, WESTERN; BRONCHI; CELLS, CULTURED; EICOSAPENTAENOIC ACID; ELECTROPHORESIS, POLYACRYLAMIDE GEL; EPOXIDE HYDROLASES; EPOXY COMPOUNDS; FLUORESCENT ANTIBODY TECHNIQUE; GUINEA PIGS; HUMANS; MICE; MUSCLE TONUS; MUSCLE, SMOOTH; MYOCYTES, SMOOTH MUSCLE; RATS; RECEPTORS, PROSTAGLANDIN E; RECEPTORS, THROMBOXANE; SIGNAL TRANSDUCTION; THROMBOXANE A2; UREA;

EID: 80055121079     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00427.2010     Document Type: Article

References (38)

1. Athirakul K, Bradbury JA, Graves JP, DeGraff LM, Ma J, Zhao Y, Couse JF, Quigley R, Harder DR, Zhao X, Imig JD, Pedersen TL, Newman JW, Hammock BD, Conley AJ, Korach KS, Coffman TM, Zeldin DC. Increased blood pressure in mice lacking cytochrome P450 2J5. FASEB J 22: 4096-4108, 2008.
2. + channel on pig coronary artery endothelial cells. J Physiol 504: 537-543, 1997.
3. Behm DJ, Ogbonna A, Wu C, Burns-Kurtis CL, Douglas SA. Epoxyeicosatrienoic acids function as selective, endogenous antagonists of native thromboxane receptors: identification of a novel mechanism of vasodilation. J Pharmacol Exp Ther 328: 231-239, 2009.
4. Benoit C, Renaudon B, Salvail D, Rousseau E. EETs relax airway smooth muscle via an EpDHF effect: BK(Ca) channel activation and hyperpolarization. Am J Physiol Lung Cell Mol Physiol 280: L965-L973, 2001.
5. Chiamvimonvat N, Ho CM, Tsai HJ, Hammock BD. The soluble epoxide hydrolase as a pharmaceutical target for hypertension. J Cardiovasc Pharmacol 50: 225-237, 2007.
6. Deng Y, Theken KN, Lee CR. Cytochrome P450 epoxygenases, soluble epoxide hydrolase, and the regulation of cardiovascular inflammation. J Mol Cell Cardiol 48: 331-341, 2010.
7. De Taeye BM, Morisseau C, Coyle J, Covington JW, Luria A, Yang J, Murphy SB, Friedman DB, Hammock BB, Vaughan DE. Expression and regulation of soluble epoxide hydrolase in adipose tissue. Obesity (Silver Spring) 18: 489-498, 2010.
8. Fang X. Soluble epoxide hydrolase: a novel target for the treatment of hypertension. Recent Pat Cardiovasc Drug Discov 1:67-72, 2006.
9. Gauthier KM, Edwards EM, Falck JR, Reddy DS, Campbell WB. 14,15- epoxyeicosatrienoic acid represents a transferable endothelium-dependent relaxing factor in bovine coronary arteries. Hypertension 45: 666-671, 2005.
10. Gross GJ, Nithipatikom K. Soluble epoxide hydrolase: a new target for cardioprotection. Curr Opin Investig Drugs 10: 253-258, 2009.
11. Haeggström JZ, Rinaldo-Matthis A, Wheelock CE, Wetterholm A. Advances in eicosanoid research, novel therapeutic implications. Biochem Biophys Res Commun 396: 135-139, 2010.
12. Imig JD. Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. Am J Physiol Renal Physiol 289: F496-F503, 2005.
13. Imig JD, Hammock BD. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov 8: 794-805, 2009.
14. Inceoglu B, Schmelzer KR, Morisseau C, Jinks SL, Hammock BD. Soluble epoxide hydrolase inhibition reveals novel biological functions of epoxyeicosatrienoic acids (EETs). Prostaglandins Other Lipid Mediat 82: 42-49, 2007.
15. Jiang H, Abel PW, Toews ML, Deng C, Casale TB, Xie Y, Tu Y. Phosphoinositide 3-kinase γ regulates airway smooth muscle contraction by modulating calcium oscillations. J Pharmacol Exp Ther 334: 703-709, 2010.
16. Kaspera R, Totah RA. Epoxyeicosatrienoic acids: formation, metabolism and potential role in tissue physiology and pathophysiology. Expert Opin Drug Metab Toxicol 5: 757-771, 2009.
17. Keserü B, Barbosa-Sicard E, Schermuly RT, Tanaka H, Hammock BD, Weissmann N, Fisslthaler B, Fleming I. Hypoxia-induced pulmonary hypertension: comparison of soluble epoxide hydrolase deletion vs. inhibition. Cardiovasc Res 85: 232-240, 2010.
18. Larsen BT, Miura H, Hatoum OA, Campbell WB, Hammock BD, Zeldin DC, Falck JR, Gutterman DD. Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids dilate human coronary arterioles via BK(Ca) channels: implications for soluble epoxide hydrolase inhibition. Am J Physiol Heart Circ Physiol 290: H491-H499, 2006.
19. Liu JY, Yang J, Inceoglu B, Qiu H, Ulu A, Hwang SH, Chiamvimonvat N, Hammock BD. Inhibition of soluble epoxide hydrolase enhances the anti-inflammatory effects of aspirin and 5-lipoxygenase activation protein inhibitor in a murine model. Biochem Pharmacol 79: 880-887, 2010.
20. Liu Y, Zhang Y, Schmelzer K, Lee TS, Fang X, Zhu Y, Spector AA, Gill S, Morisseau C, Hammock BD, Shyy JY. The anti-inflammatory effect of laminar flow: the role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc Natl Acad Sci USA 102: 16747-16752, 2005.
21. Losapio JL, Sprague RS, Lonigro AJ, Stephenson AH. 5,6-EETinduced contraction of intralobar pulmonary arteries depends on the activation of Rho-kinase. J Appl Physiol 99: 1391-1396, 2005.
22. Morisseau C, Hammock BD. Measurement of soluble epoxide hydrolase (sEH) activity. Curr Protoc Toxicol 33: 4.23.1-4.23.18, 2007.
23. Morin C, Proteau S, Rousseau E, Brayden J. Organ-cultured airway explants: a new model of airway hyperresponsiveness. Exp Lung Res 31: 719-744, 2005.
24. + channel activation and CPI-17 dephosphorylation in human bronchi. Am J Respir Cell Mol Biol 36: 633-641, 2007.
25. Morin C, Sirois M, Echave V, Gomes MM, Rousseau E. EET displays anti-inflammatory effects in TNF-alpha stimulated human bronchi: putative role of CPI-17. Am J Respir Cell Mol Biol 38: 192-201, 2008.
26. Morin C, Sirois M, Echave V, Albadine R, Rousseau E. 17,18-EpETE Targets PPARgamma and p38MAPK to mediate its anti-inflammatory effect in lung: role of sEH. Am J Respir Cell Mol Biol 43: 564-575, 2010.
27. Nakahata N. Thromboxane A2: physiology/pathophysiology, cellular signal transduction and pharmacology. Pharmacol Ther 118: 18-35, 2008.
28. Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, Zeldin DC, Liao JK. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285: 1276-1279, 1999.
29. Oguro A, Fujita N, Imaoka S. Regulation of soluble epoxide hydrolase (sEH) in mice with diabetes: high glucose suppresses sEH expression. Drug Metab Pharmacokinet 24: 438-445, 2009.
30. Przybyla-Zawislak BD, Srivastava PK, Vazquez-Matias J, Mohrenweiser HW, Maxwell JE, Hammock BD, Bradbury JA, Enayetllah AE, Zeldin DC, Grant DF. Polymorphisms in human soluble epoxide hydrolase. Mol Pharmacol 64: 482-490, 2003.
31. Revermann M. Pharmacological inhibition of the soluble epoxide hydrolase-from mouse to man. Curr Opin Pharmacol 10: 173-178, 2010.
32. Rolin S, Masereel B, Dogné JM. Prostanoids as pharmacological targets in COPD and asthma. Eur J Pharmacol 533: 89-100, 2006.
33. Sakariassen KS, Alberts P, Fontana P, Mann J, Bounameaux H, Sorensen AS. Effect of pharmaceutical interventions targeting thromboxane receptors and thromboxane synthase in cardiovascular and renal diseases. Future Cardiol 5: 479-493, 2009.
34. Shen HC. Soluble epoxide hydrolase inhibitors: a patent review. Expert Opin Ther Pat 20: 941-956, 2010.
35. Stephenson AH, Sprague RS, Losapio JL, Lonigro AJ. Differential effects of 5, 6-EET on segmental pulmonary vasoactivity in the rabbit. Am J Physiol Heart Circ Physiol 284: H2153-H2161, 2003.
36. Sun P, Liu W, Lin DH, Yue P, Kemp R, Satlin LM, Wang WH. Epoxyeicosatrienoic acid activates BK channels in the cortical collecting duct. J Am Soc Nephrol 20: 513-523, 2009.
37. Tan JZ, Kaley G, Gurtner GH. Nitric oxide and prostaglandins mediate vasodilation to 5, 6-EET in rabbit lung. Adv Exp Med Biol 407: 561-566, 1997.
38. Ye D, Zhang D, Oltman C, Dellsperger K, Lee HC, VanRollins M. Cytochrome p-450 epoxygenase metabolites of docosahexaenoate potently dilate coronary arterioles by activating large-conductance calciumactivated potassium channels. J Pharmacol Exp Ther 303: 768-776, 2002.